{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:25:08Z","timestamp":1788881108067,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,10,27]],"date-time":"2018-10-27T00:00:00Z","timestamp":1540598400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,10,27]],"date-time":"2018-10-27T00:00:00Z","timestamp":1540598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01 DA036751"],"award-info":[{"award-number":["K01 DA036751"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA044015"],"award-info":[{"award-number":["R01 DA044015"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA044015"],"award-info":[{"award-number":["R01 DA044015"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U10 DA13043"],"award-info":[{"award-number":["U10 DA13043"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R21 DA036808"],"award-info":[{"award-number":["R21 DA036808"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA044015"],"award-info":[{"award-number":["R01 DA044015"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41397-018-0065-x","type":"journal-article","created":{"date-parts":[[2018,10,27]],"date-time":"2018-10-27T03:06:07Z","timestamp":1540609567000},"page":"260-268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African\u2013Americans with opioid\u00a0use disorder"],"prefix":"10.1038","volume":"19","author":[{"given":"Richard C.","family":"Crist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karran A.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody A.","family":"Furnari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landhing M.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn A.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura F.","family":"McNicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Cornish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle M.","family":"Kampman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzie L.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade H.","family":"Berrettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,27]]},"reference":[{"key":"65_CR1","unstructured":"2015 National Survey on Drug Use and Health: Detailed Tables. Substance Abuse and Mental Health Services Administration, Rockville, MD."},{"key":"65_CR2","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014;CD002207.","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"65_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","volume":"171","author":"HR Kranzler","year":"2014","unstructured":"Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014;171:445\u201352.","journal-title":"Am J Psychiatry"},{"key":"65_CR4","first-page":"184","volume":"4","author":"C Lerman","year":"2004","unstructured":"Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharm J. 2004;4:184\u201392.","journal-title":"Pharm J"},{"key":"65_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1001\/archpsyc.65.2.135","volume":"65","author":"RF Anton","year":"2008","unstructured":"Anton RF, Oroszi G, O\u2019Malley S, Couper D, Swift R, Pettinati H, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (COMBINE) study. Arch Gen Psychiatry. 2008;65:135\u201344.","journal-title":"Arch Gen Psychiatry"},{"key":"65_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1369-1600.2012.00442.x","volume":"17","author":"AJ Chamorro","year":"2012","unstructured":"Chamorro AJ, Marcos M, Miron-Canelo JA, Pastor I, Gonzalez-Sarmiento R, Laso FJ. Association of micro-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol. 2012;17:505\u201312.","journal-title":"Addict Biol"},{"key":"65_CR7","doi-asserted-by":"publisher","first-page":"e86114","DOI":"10.1371\/journal.pone.0086114","volume":"9","author":"BB Dennis","year":"2014","unstructured":"Dennis BB, Bawor M, Thabane L, Sohani Z, Samaan Z. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis. PLoS ONE. 2014;9:e86114.","journal-title":"PLoS ONE"},{"key":"65_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/jcph.1","volume":"53","author":"ED Kharasch","year":"2013","unstructured":"Kharasch ED, Stubbert K. Role of cytochrome P4502B6 in methadone metabolism and clearance. J Clin Pharmacol. 2013;53:305\u201313.","journal-title":"J Clin Pharmacol"},{"key":"65_CR9","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/S0024-3205(97)00160-4","volume":"60","author":"C Iribarne","year":"1997","unstructured":"Iribarne C, Picart D, Dreano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997;60:1953\u201364.","journal-title":"Life Sci"},{"key":"65_CR10","first-page":"818","volume":"26","author":"K Kobayashi","year":"1998","unstructured":"Kobayashi K, Yamamoto T, Chiba K, Tani M, Shimada N, Ishizaki T, et al. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos. 1998;26:818\u201321.","journal-title":"Drug Metab Dispos"},{"key":"65_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","volume":"108","author":"RA Totah","year":"2008","unstructured":"Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology. 2008;108:363\u201374.","journal-title":"Anesthesiology"},{"key":"65_CR12","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/JCP.0b013e3182664ecd","volume":"32","author":"MR Shiran","year":"2012","unstructured":"Shiran MR, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT, et al. Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment. J Clin Psychopharmacol. 2012;32:666\u201371.","journal-title":"J Clin Psychopharmacol"},{"key":"65_CR13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2217\/pgs.14.19","volume":"15","author":"HJ Tsai","year":"2014","unstructured":"Tsai HJ, Wang SC, Liu SW, Ho IK, Chang YS, Tsai YT, et al. Assessment of CYP450 genetic variability effect on methadone dose and tolerance. Pharmacogenomics. 2014;15:977\u201386.","journal-title":"Pharmacogenomics"},{"key":"65_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1369-1600.2011.00349.x","volume":"18","author":"O Levran","year":"2013","unstructured":"Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol. 2013;18:709\u201316.","journal-title":"Addict Biol"},{"key":"65_CR15","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1093\/hmg\/ddn122","volume":"17","author":"O Levran","year":"2008","unstructured":"Levran O, O\u2019Hara K, Peles E, Li D, Barral S, Ray B, et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet. 2008;17:2219\u201327.","journal-title":"Hum Mol Genet"},{"key":"65_CR16","first-page":"53","volume":"5","author":"DT Barratt","year":"2012","unstructured":"Barratt DT, Coller JK, Hallinan R, Byrne A, White JM, Foster DJ, et al. ABCB1 haplotype and OPRM1 118A\u2009>\u2009G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmgenomics Pers Med. 2012;5:53\u201362.","journal-title":"Pharmgenomics Pers Med"},{"key":"65_CR17","first-page":"741403","volume":"2013","author":"HY Lee","year":"2013","unstructured":"Lee HY, Li JH, Sheu YL, Tang HP, Chang WC, Tang TC, et al. Moving toward personalized medicine in the methadone maintenance treatment program: a pilot study on the evaluation of treatment responses in Taiwan. Biomed Res Int. 2013;2013:741403.","journal-title":"Biomed Res Int"},{"key":"65_CR18","doi-asserted-by":"publisher","first-page":"e1005910","DOI":"10.1371\/journal.pgen.1005910","volume":"12","author":"HC Yang","year":"2016","unstructured":"Yang HC, Chu SK, Huang CL, Kuo HW, Wang SC, Liu SW, et al. Genome-wide pharmacogenomic study on methadone maintenance treatment identifies SNP rs17180299 and multiple haplotypes on CYP2B6, SPON1, and GSG1L associated with plasma concentrations of methadone R- and S-enantiomers in heroin-dependent patients. PLoS Genet. 2016;12:e1005910.","journal-title":"PLoS Genet"},{"key":"65_CR19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/mp.2016.257","volume":"22","author":"AH Smith","year":"2017","unstructured":"Smith AH, Jensen KP, Li J, Nunez Y, Farrer LA, Hakonarson H, et al. Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. Mol Psychiatry. 2017;22:346\u201352.","journal-title":"Mol Psychiatry"},{"key":"65_CR20","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.2042-7158.1959.tb10441.x","volume":"11","author":"B Oneda","year":"2011","unstructured":"Oneda B, Crettol S, Bochud M, Besson J, Croquette-Krokar M, Hammig R, et al. Beta-Arrestin2 influences the response to methadone in opioid-dependent patients. Pharm J. 2011;11:258\u201366.","journal-title":"Pharm J"},{"key":"65_CR21","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.pnpbp.2008.07.009","volume":"32","author":"S Crettol","year":"2008","unstructured":"Crettol S, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M, et al. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1722\u20137.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"65_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1601-183X.2007.00386.x","volume":"7","author":"R de Cid","year":"2008","unstructured":"de Cid R, Fonseca F, Gratacos M, Gutierrez F, Martin-Santos R, Estivill X, et al. BDNF variability in opioid addicts and response to methadone treatment: preliminary findings. Genes Brain Behav. 2008;7:515\u201322.","journal-title":"Genes Brain Behav"},{"key":"65_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/00004714-200104000-00016","volume":"21","author":"CB Eap","year":"2001","unstructured":"Eap CB, Broly F, Mino A, Hammig R, Deglon JJ, Uehlinger C, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol. 2001;21:229\u201334.","journal-title":"J Clin Psychopharmacol"},{"key":"65_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","volume":"128","author":"AJ Saxon","year":"2013","unstructured":"Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, et al. Buprenorphine\/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend. 2013;128:71\u201376.","journal-title":"Drug Alcohol Depend"},{"key":"65_CR25","first-page":"303","volume":"14","author":"TK Clarke","year":"2014","unstructured":"Clarke TK, Crist RC, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, et al. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharm J. 2014;14:303\u20138.","journal-title":"Pharm J"},{"issue":"1","key":"65_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/tpj.2016.89","volume":"18","author":"R C Crist","year":"2016","unstructured":"Crist RC, Doyle GA, Nelson EC, Degenhardt L, Martin NG, Montgomery GW, et al. A polymorphism in the OPRM1 3\u2019-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics J. 2018; 18:173-9.","journal-title":"The Pharmacogenomics Journal"},{"key":"65_CR27","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1038\/npp.2013.99","volume":"38","author":"RC Crist","year":"2013","unstructured":"Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, et al. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology. 2013;38:2003\u201310.","journal-title":"Neuropsychopharmacology"},{"key":"65_CR28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/sj.mp.4002035","volume":"13","author":"H Zhang","year":"2008","unstructured":"Zhang H, Kranzler HR, Yang BZ, Luo X, Gelernter J. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry. 2008;13:531\u201343.","journal-title":"Mol Psychiatry"},{"key":"65_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.drugalcdep.2008.11.006","volume":"101","author":"DH Epstein","year":"2009","unstructured":"Epstein DH, Schmittner J, Umbricht A, Schroeder JR, Moolchan ET, Preston KL. Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. Drug Alcohol Depend. 2009;101:92\u2013100.","journal-title":"Drug Alcohol Depend"},{"key":"65_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1001\/archgenpsychiatry.2008.509","volume":"66","author":"DH Epstein","year":"2009","unstructured":"Epstein DH, Willner-Reid J, Vahabzadeh M, Mezghanni M, Lin JL, Preston KL. Real-time electronic diary reports of cue exposure and mood in the hours before cocaine and heroin craving and use. Arch Gen Psychiatry. 2009;66:88\u201394.","journal-title":"Arch Gen Psychiatry"},{"key":"65_CR31","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1176\/appi.ajp.2014.14081014","volume":"172","author":"WJ Kowalczyk","year":"2015","unstructured":"Kowalczyk WJ, Phillips KA, Jobes ML, Kennedy AP, Ghitza UE, Agage DA, et al. Clonidine maintenance prolongs opioid abstinence and decouples stress from craving in daily life: a randomized controlled trial with ecological momentary assessment. Am J Psychiatry. 2015;172:760\u20137.","journal-title":"Am J Psychiatry"},{"key":"65_CR32","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1901\/jaba.2008.41-551","volume":"41","author":"KL Preston","year":"2008","unstructured":"Preston KL, Ghitza UE, Schmittner JP, Schroeder JR, Epstein DH. Randomized trial comparing two treatment strategies using prize-based reinforcement of abstinence in cocaine and opiate users. J Appl Behav Anal. 2008;41:551\u201363.","journal-title":"J Appl Behav Anal"},{"issue":"17","key":"65_CR33","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1007\/s00213-017-4663-0","volume":"234","author":"Kenzie L. Preston","year":"2017","unstructured":"Preston KL, Kowalczyk WJ, Phillips KA, Jobes ML, Vahabzadeh M, Lin JL, et al. Context and craving during stressful events in the daily lives of drug-dependent patients. Psychopharmacology (Berl). 2017; 234:2631-42.","journal-title":"Psychopharmacology"},{"key":"65_CR34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugalcdep.2012.06.023","volume":"127","author":"RC Crist","year":"2013","unstructured":"Crist RC, Ambrose-Lanci LM, Vaswani M, Clarke TK, Zeng A, Yuan C, et al. Case-control association analysis of polymorphisms in the delta-opioid receptor, OPRD1, with cocaine and opioid addicted populations. Drug Alcohol Depend. 2013;127:122\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"65_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1046\/j.1360-0443.1998.931738.x","volume":"93","author":"DD Brewer","year":"1998","unstructured":"Brewer DD, Catalano RF, Haggerty K, Gainey RR, Fleming CB. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction. 1998;93:73\u201392.","journal-title":"Addiction"},{"key":"65_CR36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1526-4637.2011.01075.x","volume":"12","author":"HG Birnbaum","year":"2011","unstructured":"Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12:657\u201367.","journal-title":"Pain Med"},{"key":"65_CR37","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/02791072.2017.1290303","volume":"49","author":"A Sharafshah","year":"2017","unstructured":"Sharafshah A, Fazel H, Albonaim A, Omarmeli V, Rezaei S, Mirzajani E, et al. Association of OPRD1 gene variants with opioid dependence in addicted male individuals undergoing methadone treatment in the north of Iran. J Psychoact Drugs. 2017;49:242\u201351.","journal-title":"J Psychoact Drugs"},{"key":"65_CR38","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1002\/hbm.22247","volume":"35","author":"FF Roussotte","year":"2014","unstructured":"Roussotte FF, Jahanshad N, Hibar DP, Sowell ER, Kohannim O, Barysheva M, et al. A commonly carried genetic variant in the delta opioid receptor gene, OPRD1, is associated with smaller regional brain volumes: replication in elderly and young populations. Hum Brain Mapp. 2014;35:1226\u201336.","journal-title":"Hum Brain Mapp"},{"key":"65_CR39","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2217\/epi.12.18","volume":"4","author":"LH Chadwick","year":"2012","unstructured":"Chadwick LH. The NIH Roadmap Epigenomics Program data resource. Epigenomics. 2012;4:317\u201324.","journal-title":"Epigenomics"},{"issue":"D1","key":"65_CR40","doi-asserted-by":"publisher","first-page":"D877","DOI":"10.1093\/nar\/gkv1340","volume":"44","author":"LD Ward","year":"2016","unstructured":"Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res. 2016;44(D1):D877\u201381.","journal-title":"Nucleic Acids Res"},{"key":"65_CR41","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1126\/science.1262110","volume":"348","author":"The GTEx Consortium. Human genomics.","year":"2015","unstructured":"The GTEx Consortium. Human genomics. The Genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348:648\u201360.","journal-title":"Science"},{"issue":"4","key":"65_CR42","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1007\/s12035-018-1253-z","volume":"56","author":"Marjo Piltonen","year":"2018","unstructured":"Piltonen M, Parisien M, Gregoire S, Chabot-Dore AJ, Jafarnejad SM, Berube P, et al. Alternative Splicing of the delta-opioid receptor gene suggests existence of new functional isoforms. Mol Neurobiol 2018 https:\/\/doi.org\/10.1007\/s12035-018-1253-z .","journal-title":"Molecular Neurobiology"},{"key":"65_CR43","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/00008877-200211000-00005","volume":"13","author":"SS Negus","year":"2002","unstructured":"Negus SS, Bidlack JM, Mello NK, Furness MS, Rice KC, Brandt MR. Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behav Pharmacol. 2002;13:557\u201370.","journal-title":"Behav Pharmacol"},{"key":"65_CR44","doi-asserted-by":"crossref","first-page":"23055","DOI":"10.1016\/S0021-9258(19)49424-6","volume":"268","author":"H Kong","year":"1993","unstructured":"Kong H, Raynor K, Yasuda K, Moe ST, Portoghese PS, Bell GI, et al. A single residue, aspartic acid 95, in the delta opioid receptor specifies selective high affinity agonist binding. J Biol Chem. 1993;268:23055\u20138.","journal-title":"J Biol Chem"},{"key":"65_CR45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0026-895X(25)13131-3","volume":"44","author":"MM Belcheva","year":"1993","unstructured":"Belcheva MM, Barg J, McHale RJ, Dawn S, Ho MT, Ignatova E, et al. Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine. Mol Pharmacol. 1993;44:173\u20139.","journal-title":"Mol Pharmacol"},{"key":"65_CR46","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/S0022-3565(25)13078-4","volume":"277","author":"MM Belcheva","year":"1996","unstructured":"Belcheva MM, Ho MT, Ignatova EG, Jefcoat LB, Barg J, Vogel Z, et al. Buprenorphine differentially alters opioid receptor adaptation in rat brain regions. J Pharmacol Exp Ther. 1996;277:1322\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"65_CR47","doi-asserted-by":"publisher","first-page":"11152","DOI":"10.1074\/jbc.M500171200","volume":"280","author":"PY Law","year":"2005","unstructured":"Law PY, Erickson-Herbrandson LJ, Zha QQ, Solberg J, Chu J, Sarre A, et al. Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions. J Biol Chem. 2005;280:11152\u201364.","journal-title":"J Biol Chem"},{"key":"65_CR48","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0014-2999(99)00322-2","volume":"374","author":"JG Liu","year":"1999","unstructured":"Liu JG, Liao XP, Gong ZH, Qin BY. Methadone-induced desensitization of the delta-opioid receptor is mediated by uncoupling of receptor from G protein. Eur J Pharmacol. 1999;374:301\u20138.","journal-title":"Eur J Pharmacol"},{"key":"65_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.addbeh.2017.05.010","volume":"73","author":"AJ Damian","year":"2017","unstructured":"Damian AJ, Mendelson T, Agus D. Predictors of buprenorphine treatment success of opioid dependence in two Baltimore City grassroots recovery programs. Addict Behav. 2017;73:129\u201332.","journal-title":"Addict Behav"},{"key":"65_CR50","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1111\/j.1530-0277.2000.tb04571.x","volume":"24","author":"JR Mertens","year":"2000","unstructured":"Mertens JR, Weisner CM. Predictors of substance abuse treatment retention among women and men in an HMO. Alcohol Clin Exp Res. 2000;24:1525\u201333.","journal-title":"Alcohol Clin Exp Res"},{"key":"65_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0376-8716(00)00155-1","volume":"62","author":"ME McCaul","year":"2001","unstructured":"McCaul ME, Svikis DS, Moore RD. Predictors of outpatient treatment retention: patient versus substance use characteristics. Drug Alcohol Depend. 2001;62:9\u201317.","journal-title":"Drug Alcohol Depend"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41397-018-0065-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-018-0065-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-018-0065-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T22:06:02Z","timestamp":1775253962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-018-0065-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,27]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["65"],"URL":"https:\/\/doi.org\/10.1038\/s41397-018-0065-x","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,27]]},"assertion":[{"value":"27 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KMK has received consulting fees from Alkermes and Opiant Pharmaceuticals. He has also received grant funding from Alkermes, Opiant Pharmaceuticals, and Indivior. WHB has received consulting fees from Mundipharma and Geisinger Health Systems and grant support from Saniona. The remaining authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}